

NCI Update

*Douglas R. Lowy
Acting Director, National Cancer Institute,
National Institutes of Health*

Outline of Presentation

- NCI budget: FY16 and FY17 proposal
- Vice President's cancer initiative

Outlook for Cancer Research Funding

- Strong bipartisan support for NCI/NIH
 - Need/opportunity
 - Key role of advocacy
 - Faster progress for patients
- Potential for continuing increases in Federal cancer research funding
- Coordination with private funding efforts

**NCI FY16
Appropriation:
A ~5% increase**


- ~\$265 million total increase
- \$70 million: the President's Precision Medicine Initiative in Oncology (PMI-O)
- \$195 million: Non-PMI-O increase

RPG pool for FY17

- Add ~\$50 million to non-competing awards (type 5)
 - Enables continued support at 100% commitment level
- Add ~\$53 million to new and competing awards (types 1 & 2)
 - ~\$447 million became available for FY17 from awards that were ending

NCI BUDGET 2005 – 2015: A PERIOD OF LEVEL BUDGETS & PROGRESSIVELY DECREASING PURCHASING POWER

FY 2016 & 2017: AN ENCOURAGING TREND



----- The dashed line at approximately \$3.3 billion indicates that the inflation-adjusted FY 2017 proposed budget is similar to the FY 2000 budget

The Vice President's Cancer Initiative

- Accelerate progress in cancer, including prevention & screening
 - From cutting edge basic research to wider uptake of standard of care
- Encourage greater cooperation and breaking down silos
 - Within and between academia, government, and private sector
- Importance of data sharing: Genomic Data Commons, annotated patient level clinical data & -omics

Vice President Biden on the Initiative

- “My commitment is not for the next 12 months...I plan on doing this the rest of my life.”
- “I'm not naive to think we're going to find a cure. We're talking about prevention and early detection. I'm convinced we can get answers and come up with game-changing treatments and get them to people who need them. We have an opportunity to fundamentally change the trajectory.”

University of Pennsylvania Abramson Cancer Center, January 15, 2016

Proposed for Prevention, Screening, and Implementation

- Develop preventive interventions (e.g., vaccines) against infectious and non-infectious targets
- Develop screening tests with body fluid samples (e.g, blood, urine, saliva)
- Increase uptake of standard of care for prevention, screening, and treatment

Proposed for Cancer Treatment: Clinical and pre-clinical

- Increase immunotherapy trials and combination therapy trials
- Increase patient participation in clinical trials
- Develop new treatments for pediatric cancer
- Develop a drug formulary from many companies at NCI
 - To facilitate the study of combination therapy
- Expand -omic analysis of tumor cells and stromal cells for patients with clinical annotation

Other Proposed Research

- Develop drugs for pediatric cancer
- Increase preclinical studies of therapeutic cancer vaccines and cancer immunotherapy
- Increase basic research, especially in immunology
- Develop an “exceptional opportunities fund”



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol